Across Pharmacies and Supply Chains: Poland Penalizes Wholesalers After Years of Sensitive Data Exchanges

Medicine moves through a long chain before reaching a pharmacy counter. Behind every box on a shelf are manufacturers, wholesalers, distributors and pharmacies, connected by contracts, prices and information that determine how products move through the market.

In Poland, that chain has become the center of a major competition case. The country’s Office of Competition and Consumer Protection, UOKiK, imposed fines totaling more than PLN900 million on pharmaceutical wholesalers over the exchange of commercially sensitive information.

The penalties total approximately PLN905 million, or more than €200 million depending on the exchange rate used. The companies involved include Neuca, Farmacol-Logistyka, Farmacol and Świat Zdrowia. Polska Grupa Farmaceutyczna avoided a financial penalty after cooperating with investigators under the authority’s leniency program.

According to UOKiK, the information exchange continued for more than a decade. The wholesalers obtained data concerning prices, sales volumes and commercial terms offered to individual pharmacies, using information collected through pharmacy partnership programs and related IT systems.

The information was not simply general market data. According to the authority, the systems could provide detailed information about what particular pharmacies purchased from competing wholesalers and the terms attached to those transactions.

UOKiK concluded that the exchange reduced uncertainty between competitors and weakened incentives for aggressive price competition. The authority said that access to competitors’ nonpublic commercial information allowed wholesalers to adjust their own offers with greater knowledge of what rivals were doing.

The case concerns some of the largest participants in Poland’s pharmaceutical wholesale market. According to reporting on the UOKiK decision, the Neuca, Farmacol and Polska Grupa Farmaceutyczna groups together accounted for more than 70% of the wholesale medicines market between 2015 and 2022.

The competition authority’s decision does not represent the end of the legal process. The decision remains subject to appeal, and companies affected by the penalties have indicated that they may challenge the findings.

The case also highlights a broader issue in modern commerce: information itself can become a powerful market asset. When competitors have access to detailed data about one another’s customers, prices and commercial terms, the distinction between legitimate market intelligence and problematic information sharing can become particularly important.

For the pharmaceutical sector, that distinction carries consequences beyond corporate balance sheets. Wholesalers sit between manufacturers and pharmacies, meaning changes in the competitive conditions of distribution can eventually influence the terms offered to pharmacies and, potentially, the wider medicine market. UOKiK has said its findings showed that weaker competition could affect commercial conditions for pharmacies and patients.

Poland’s decision therefore brings a long-running information network into public view. The fines mark a significant stage in the case, while appeals and the publication of further legal details will determine how the findings develop. Behind the numbers is a broader lesson about the growing importance of data in healthcare markets, where information can move almost as quietly as the medicines themselves.